A detailed history of Gsa Capital Partners LLP transactions in Aerovate Therapeutics, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 413,795 shares of AVTE stock, worth $1.06 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
413,795
Previous 126,632 226.77%
Holding current value
$1.06 Million
Previous $210,000 311.9%
% of portfolio
0.07%
Previous 0.01%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

BUY
$1.61 - $2.09 $462,332 - $600,170
287,163 Added 226.77%
413,795 $865,000
Q2 2024

Aug 15, 2024

BUY
$1.41 - $30.75 $178,551 - $3.89 Million
126,632 New
126,632 $210,000

Others Institutions Holding AVTE

About Aerovate Therapeutics, Inc.


  • Ticker AVTE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,448,100
  • Market Cap $62.6M
  • Description
  • Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which ...
More about AVTE
Track This Portfolio

Track Gsa Capital Partners LLP Portfolio

Follow Gsa Capital Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.